Benefits
GLP-1 secretion: one sponsor-funded single-dose study
In a single-blind, fixed-sequence crossover study funded by the supplier (37 adults with a BMI of 25 to 34.9), a single 300 mg dose raised GLP-1 about 20 to 25% above placebo at key timepoints, with a similar rise in GIP. Total GLP-1 over 8 hours did not differ from placebo, insulin and glucose did not change, and 150 mg did no better than placebo. Over 12 weeks of daily use, the GLP-1 rise did not reach significance.
Akkermansia muciniphila enrichment
In adults with obesity (BMI 30 to 40), Trpti at 300 mg a day for 12 weeks increased Akkermansia muciniphila, a gut bacterium linked to gut barrier function, while overall microbial diversity stayed stable. This is a stool sequencing result, not a health outcome, and no trial has shown that raising Akkermansia with this ingredient changes how people feel or function.
Faecalibacterium prausnitzii enrichment
The same obesity trial documented enrichment of Faecalibacterium prausnitzii, another beneficial gut bacterium associated with anti-inflammatory effects and gut barrier integrity. How a compound that is neither a prebiotic nor a probiotic shifts these species is not established; direct gut signaling by OEA is one proposed explanation, but the trial did not test the mechanism.
Intestinal barrier marker (occludin) higher at 12 weeks
In the 12-week trial, blood occludin, a tight-junction protein, was higher than on placebo at week 12. Other barrier markers measured (zonulin, claudin-1 and mucin-2) did not change. These are laboratory markers rather than measures of digestive comfort, and whether they translate into any difference in symptoms has not been tested.
Immune modulation (IL-2 up, IL-1β down)
In the 12-week trial, IL-2 (a signaling protein of the immune system) was higher than on placebo at week 6, and IL-1β (an inflammatory signal) was lower than on placebo at week 6. These are single laboratory measurements whose meaning is uncertain, and they do not show that immune function or infection risk changed.
Appetite and body weight in generic OEA trials
In a small trial of plain OEA (250 mg a day for 8 weeks, 56 adults with obesity analysed), hunger and weight fell in the OEA group. A pooled analysis of 4 trials found a small weight reduction that lost significance when either of two trials was removed. In the 12-week Trpti trial, weight did not change overall; in those with a BMI under 35, it fell 1.6 kg versus a 1.2 kg gain on placebo.
PPAR-α activation mechanism
OEA binds PPAR-alpha, a nuclear receptor that promotes fat breakdown, fat burning and fullness. In animal studies, PPAR-alpha activation in the small intestine signals fullness to the brain through vagal nerves. In people, lower appetite and food intake have been reported in two reports of one small trial of plain OEA from a single research group.
Lower triglyceride and glucose markers in generic OEA trials
In two small trials of generic OEA, not Trpti, 250 mg/day for 8 weeks in 60 adults with obesity lowered triglycerides vs placebo but not fasting glucose or cholesterol, and 12 weeks in 76 adults with obesity and fatty liver on a calorie-restricted diet lowered triglycerides and glycemic markers except HbA1c. Pooled glucose and insulin results (3 to 4 trials) varied widely. A single Trpti dose did not change glucose or insulin.
Mechanism of action
PPAR-α nuclear receptor binding
OEA binds peroxisome proliferator-activated receptor-alpha (PPAR-α), a nuclear receptor that regulates fat metabolism, fullness and energy balance. In animal studies, PPAR-α activation increases fat burning in liver and muscle, promotes fat breakdown in fat tissue and signals fullness to the brain through vagal nerves from the small intestine.
Intestinal L-cell GLP-1 secretion
In cell and animal models, OEA stimulates GLP-1 release from intestinal L-cells rather than binding GLP-1 receptors directly. In people, one sponsor-funded single-dose study of Trpti found GLP-1 above placebo at some timepoints but not over the full 8 hours, so whether regular oral OEA meaningfully changes GLP-1 levels is unproven. No comparison with prescription medicines is implied or supported.
Vagal afferent satiety signaling
In animal studies, OEA activates vagal sensory nerves in the small intestine that relay to brain areas controlling fullness, reducing later food intake. This gut-brain pathway has not been measured directly in people taking OEA.
LipiSperse® dispersion technology
LipiSperse is a cold-water dispersion technology from Pharmako Biotechnologies (Australia), designed to help poorly soluble lipids such as OEA mix in water. No published human study has compared the absorption of LipiSperse-delivered OEA with plain OEA, and the generic OEA trials cited on this page did not use this delivery system.
Proposed gut microbiome modulation
OEA's effects on Akkermansia muciniphila and Faecalibacterium prausnitzii enrichment occur without the supplement itself being a prebiotic or probiotic. Mechanism may involve OEA's effects on intestinal mucus production, gut motility, and microenvironmental conditions that favor these beneficial species. A bidirectional relationship, in which gut bacteria in turn influence endogenous OEA production, has been proposed but was not tested in the trials cited here.
Endocannabinoid-like signaling
OEA is an N-acyl ethanolamide, structurally related to anandamide and palmitoylethanolamide (PEA). Unlike anandamide, OEA does not act mainly through the CB1 or CB2 cannabinoid receptors; its known targets include PPAR-α and TRPV1.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Trpti 300 mg a day (at least 250 mg OEA) vs placebo for 12 weeks, measuring stool metagenomics, gut barrier and inflammatory blood markers, body measurements and questionnaires; funded by Gencor Pacific (Batacan et al. 2026, Gut Microbes Rep).
57 adults with obesity (BMI 30 to 40) enrolled; 44 completed.
Akkermansia muciniphila and Faecalibacterium prausnitzii increased while overall microbial diversity stayed stable. Versus placebo, occludin was higher at week 12, IL-2 higher at week 6 and IL-1β lower at week 6; zonulin, claudin-1 and mucin-2 did not change, and GLP-1 showed only a non-significant trend. Body weight did not differ overall; in a subgroup with BMI under 35, weight fell about 1.6 kg versus a 1.2 kg gain on placebo. Quality-of-life, stress and sleep questionnaires did not differ. No adverse changes were seen in safety blood tests.
Single-blind, placebo-controlled, three-period crossover study in which participants took single doses of placebo, Trpti 150 mg and Trpti 300 mg in a set order rather than a randomized one, with standard breakfast and lunch and blood sampling over 8 hours (NCT06840080). Registered primary endpoint: change in GLP-1 AUC, analysed by pre-specified meal periods. Funded by Gencor Pacific; one author is a sponsor employee, and the staff giving the products were not blinded (Briskey et al. 2026, Front Endocrinol).
37 adults analysed (40 enrolled), BMI 25 to 34.9 kg/m², with no known glucose or insulin disorder.
300 mg raised GLP-1 more than placebo in the first 30 minutes and at 3 to 4 hours, with GLP-1 about 20 to 25% above placebo at key timepoints and similar rises in GIP. Over the full 8 hours, total GLP-1 did not differ between 300 mg and placebo (p=0.162). Insulin, glucose and glucagon did not differ between groups. Both doses left more of the lunch meal uneaten than placebo. The 150 mg dose did no better than placebo, ran below it in several periods, and started from a higher pre-dose GLP-1 level. These are single-dose results; in the separate 12-week trial, the GLP-1 rise did not reach significance.